pharmaceutical company
AbbVie lifts profit forecast after Skyrizi sales beat expectations: AbbVie raised its annual profit forecast on Friday after strong sales of its immunology drug ...
reuters.com/business/healthcare-pharmaceuticals/abbvie-raises-annual-profit-forecast-strong-skyrizi-sales-2024-04-26/
AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
reuters.com/business/healthcare-pharmaceuticals/abbvies-skin-disease-drug-found-be-more-effective-than-regenerons-dupixent-study-2024-04-25/
Biosimilars 102: Interchangeability, Extrapolation, and Immunogenicity -- A Regulatory Process Primer
medscape.org/viewarticle/999867
US CDC warns of harmful reactions to fake Botox injections: The U.S. Centers for Disease Control and Prevention (CDC) on Tuesday alerted clinicians about risks ...
reuters.com/business/healthcare-pharmaceuticals/us-cdc-warns-harmful-reactions-fake-botox-injections-2024-04-23/
AbbVie Raises Earnings Guidance Even as Humira Sales Continue to Drop: AbbVie reports better-than-expected adjusted earnings in the first quarter.
barrons.com/articles/abbvie-earnings-stock-price-cd6c5343
Paid articlePaid
AbbVie Is ‘One of the Best Positioned’ Large Cap Stocks: J.P. Morgan analyst Chris Schott rates AbbVie as Overweight with a $190 price target.
on.barrons.com/440MbXJ
AbbVie: Great To Be Proven Wrong - Still Not A Buy: AbbVie outperformed expectations, with Humira remaining the market leader with 98% share despite LOE and ...
seekingalpha.com/article/4683574-abbvie-great-to-be-proven-wrong-still-not-a-buy
Paid articlePaid Cigna to offer Humira rivals with $0 copay at specialty pharmacy: Cigna plans to make close copies of AbbVie's blockbuster arthritis drug Humira available with ...
reuters.com/business/healthcare-pharmaceuticals/cigna-offer-humira-rivals-with-0-copay-specialty-pharmacy-2024-04-25/
US FDA warns of harmful reactions to fake Botox injections: The U.S. Food and Drug Administration on Tuesday alerted health care professionals and consumers that ...
reuters.com/business/healthcare-pharmaceuticals/us-fda-warns-harmful-reactions-fake-botox-injections-2024-04-16/
AbbVie: Still Fits Buffett's 10x EBT Rule Well Despite Guidance Revision: AbbVie's stock price fell by about 7% last week after the company revised its full-year ...
seekingalpha.com/article/4682695-abbvie-still-fits-buffett-10x-ebt-rule-despite-guidance-revision
Paid articlePaid
A new drug to prevent migraines will soon become available on the NHS 🙌Migraine breakthrough as new pill offered on NHS for the first time - LancsLive
Abbvie: New building strengthens research in Ludwigshafen: Abbvie: New building strengthens research in Ludwigshafen - major project - THE RHEINPALAZZ
rheinpfalz.de/lokal/pfalz-ticker_artikel,-abbvie-neubau-st%C3%A4rkt-forschung-in-ludwigshafen-_arid,5637367.html
Humira biosimilar scripts take off: It marked one of the first major efforts to push biosimilar adoption.
axios.com/2024/04/16/humira-biosimilar-prescribing-surge
The Age of Respiratory Syncytial Virus Prevention: Empowering Pharmacists to Optimize Disease Protection in Older Adults
medscape.org/viewarticle/999447
We Just Upgraded These 6 Companies. Is It Time to Buy the Stocks?: We’ve boosted the Morningstar Economic Moat Ratings on these companies to wide.
morningstar.com/stocks/we-just-upgraded-these-6-companies-is-it-time-buy-stocks-2
We Just Upgraded These 6 Companies. Is It Time to Buy the Stocks?: We’ve boosted the Morningstar Economic Moat Ratings on these companies to wide.
morningstar.com/stocks/we-just-upgraded-these-6-companies-is-it-time-buy-stocks-2
Boehringer to lay off salespeople as Humira biosimilar sales lag: Boehringer Ingelheim on Thursday said it will lay off some of its salesforce due to poor U.S ...
reuters.com/business/healthcare-pharmaceuticals/boehringer-lay-off-salespeople-humira-biosimilar-sales-lag-2024-04-04/
US FDA grants full approval to AbbVie's ovarian cancer therapy: The U.S. Food and Drug Administration said on Friday it had granted traditional approval for ...
reut.rs/496Piyi
Aldeyra: Derisked Biotech Eyeing Path To Approval And Finalizing Deal With AbbVie
seekingalpha.com/article/4680108-aldeyra-derisked-biotech-eyeing-path-to-approval-and-finalizing-deal-with-abbvie
Paid articlePaid
AbbVie’s New ‘Biological Missile’ Ovarian Cancer Treatment Gets Full FDA Approval
forbes.com/sites/jamesfarrell/2024/03/22/abbvies-new-biological-missile-ovarian-cancer-treatment-gets-full-fda-approval/
🚀 Introducing the Immunology Learning Nexus - co-chaired by Drs Peter Lio, Philip Mease, and David Rubin. Dive into our new activities designed to improve ... Show more
ms.spr.ly/6188cVS6C
ms.spr.ly/6188cVS6C
AbbVie Selling $15 Billion Bonds to Buy ImmunoGen, Cerevel: Pharmaceutical giant AbbVie Inc. is selling around $15 billion of bonds in the US investment-grade ...
trib.al/B3ibuW7
MoonLake Jumps As It Looks To Take On AbbVie Blockbuster, Humira: Biotech stock MoonLake popped Monday after the company said its experimental psoriatic ...
investors.com/news/technology/biotech-stock-moonlake-psoriatic-arthritis-treatment-abbvie-humira/
AbbVie Names New CEO. The Stock’s Not Moving.
barrons.com/articles/abbvie-new-ceo-stock-bb8044b3
Paid articlePaid Join us to engage with a multidisciplinary expert faculty panel on the current evidence and clinical considerations for JAK inhibitors across immune-mediated ... Show more
Biotechnology in RLP: These projects are planned: The pharmaceutical company Eli Lilly is building in Alzey, a biotech campus is being built in Mainz and Abbvie ...
allgemeine-zeitung.de/politik/politik-rheinland-pfalz/biotechnologie-in-rlp-diese-projekte-sind-geplant-3449339
Maryland drug affordability board considers eight drugs for first cost review: The state's Prescription Drug Affordability Board is considering eight drugs ...
baltimoresun.com/2024/03/26/prescription-drug-affordability/
AbbVie Q4: Now Isn't The Time To Buy My Largest Big Pharma Holding: AbbVie's valuation is the only thing that I don't like about it at this moment ...
seekingalpha.com/article/4668186-abbvie-q4-now-isnt-the-time-to-buy-my-largest-big-pharma-holding
Paid articlePaid AbbVie Inc. (ABBV) Barclays 26th Annual Global Healthcare Conference (Transcript)
seekingalpha.com/article/4678277-abbvie-inc-abbv-barclays-26th-annual-global-healthcare-conference-transcript
My portfolio is worth over 100,000 euros: My 5 strongest stocks: Nico Söldner's portfolio now totals a six-figure sum. That's why he relies on individual stocks ...
businessinsider.de/wirtschaft/finanzen/mein-depot-ist-ueber-100-000-euro-wert-meine-5-staerksten-aktien/
Shell, AbbVie, Porsche: The investment tips of the week: Shell is giving up the green vest, AbbVie could turn things around faster than expected and Porsche is ...
wiwo.de/my/finanzen/geldanlage/shell-abbvie-porsche-das-sind-die-anlagetipps-der-woche/29692814.html
Paid articlePaid
Humira drug competitors lag despite their lower price tags: The failure of Humira’s competitors to gain much traction — so far, at least — helps illustrate the ...
bostonglobe.com/2024/03/05/business/humira-abbvie-drug-competitor-cost-biosimilar/
News from the bond market: taking on debt for acquisitions: In the past two weeks alone, American corporations have issued corporate bonds worth around $50 ...
faz.net/aktuell/finanzen/neues-vom-anleihemarkt-schulden-aufnehmen-fuer-zukaeufe-19552023.html
Live on dividends with these three great and stable stocks: Discover three top dividend stocks: Nestlé, AbbVie and Public Storage, with stable payouts for ...
boerse-online.de/nachrichten/aktien/von-dividenden-leben-mit-diesen-drei-grossartigen-und-stabilen-aktien-20351369.html
AbbVie Posts Revenue Beat as Humira Sales Tumble. Other Immunology Drugs Are Selling.
on.barrons.com/49k795j
Why Aldeyra Therapeutics Is A Strong Buy: AbbVie Agreement And Reproxalap's Prospects
seekingalpha.com/article/4665589-why-aldeyra-therapeutics-strong-buy-abbvie-agreement-and-reproxalaps-prospects
Paid articlePaid
‘Ozempic Face’ Is Expected to Boost to Botox Sales: AbbVie Inc. sees “Ozempic face” — the saggy, hollowed out look some patients report after taking weight-loss ...
bloomberg.com/news/articles/2024-02-02/-ozempic-face-is-expected-to-boost-to-botox-sales
AbbVie (ABBV) Sees Signs of Post-Humira Growth in Positive 2024 Outlook: AbbVie Inc. boosted 2024 forecasts as strong growth in newer anti-inflammatory ...
bloomberg.com/news/articles/2024-02-02/abbvie-sees-signs-of-post-humira-growth-in-positive-2024-outlook
AbbVie Inc. (ABBV) Q4 2023 Earnings Call Transcript: AbbVie Inc. (NYSE:NYSE:ABBV) Q4 2023 Earnings Conference Call February 2, 2024 9:00 AM ETCompany ...
seekingalpha.com/article/4667147-abbvie-inc-abbv-q4-2023-earnings-call-transcript
AbbVie Q4 Review: Stock Remains A Buy, Encouraged By Skyrizi And Rinvoq: AbbVie's Q4 revenue beat expectations, a positive sign considering the expiration of ...
seekingalpha.com/article/4667814-abbvie-q4-review-stock-remains-buy-encouraged-by-skyrizi-and-rinvoq
Paid articlePaid CVS Caremark, the pharmaceutical subsidiary of CVS Health, announced Wednesday it will replace AbbVie’s Humira from its list of covered drugs with cheaper ... Show more
AbbVie expects Botox to maintain market share as competition heats up: AbbVie (ABBV.N) expects Botox's market share in the aesthetics space to remain strong even ...
reuters.com/business/healthcare-pharmaceuticals/abbvie-expects-botox-market-share-stay-strong-despite-newer-rivals-2024-01-10/
ROS1-Positive Advanced NSCLC: Sharing Best Practice From the Clinic to Maximize Patient Outcomes
medscape.org/viewarticle/998606
Too much bureaucracy: frustration among players like BASF, Abbvie and the Klinikum
rheinpfalz.de/lokal/ludwigshafen_artikel,-zu-viel-b%C3%BCrokratie-frust-bei-akteuren-wie-basf-abbvie-und-dem-klinikum-_arid,5607805.html
AbbVie lawsuit says rival Adcentrx stole anti-cancer secrets: Pharmaceutical company AbbVie (ABBV.N) has sued startup Adcentrx Therapeutics in California federal ...
reuters.com/legal/litigation/abbvie-lawsuit-says-rival-adcentrx-stole-anti-cancer-secrets-2023-12-18/
Cytokinetics (CYTK) Share Price Soars as Heart Drug Aficamten Hits Goal in Trial: Cytokinetics Inc. said its experimental drug helped patients with a genetic ...
bloomberg.com/news/articles/2023-12-27/cytokinetics-soars-as-heart-drug-hits-goal-in-late-stage-trial
Paid articlePaid Is Primary Biliary Cholangitis on Your Radar? : Did you know that primary biliary cholangitis (PBC) is the most common of the autoimmune liver diseases? Hear ...
medscape.org/viewarticle/998621
A new test could save arthritis patients time, money and pain. But will it be used?
npr.org/sections/health-shots/2023/12/20/1220426603/rheumatoid-arthritis-precision-medicine-humira
AbbVie and Big Pharma Have Floundered. How That Could Change in 2024.
barrons.com/articles/abbvie-big-pharma-outlook-344b2bdd
Paid articlePaid AbbVie's $8.7 bln bet on Cerevel is risky but smart, analysts say: AbbVie's (ABBV.N) decision to buy Cerevel Therapeutics (CERE.O) before key data on the drug ...
reuters.com/business/healthcare-pharmaceuticals/abbvies-87-bln-bet-cerevel-is-risky-smart-analysts-say-2023-12-07/
AbbVie To Buy ImmunoGen, Cancer Drug Maker, In $10.1 Billion Cash Deal: IMGN stock soared after AbbVie agreed to buy ImmunoGen for $10.1 billion ...
investors.com/news/technology/imgn-stock-abbv-stock-biotech-acquisition-elahere/
AbbVie expects Botox to maintain market share as competition heats up: AbbVie (ABBV.N) expects Botox's market share in the aesthetics space to remain strong even ...
reuters.com/business/healthcare-pharmaceuticals/abbvie-expects-botox-market-share-stay-strong-despite-newer-rivals-2024-01-10/
Quick Glance: VW utilizing ChatGPT for driver conversations by mid-year
- Volkswagen integrating ChatGPT to enable driver conversations by mid-year.
- First vehicles with ChatGPT available in North America and Europe from early second quarter.
- AI system capable of recognizing and responding to various demands, such as temperature adjustments and displaying nearby restaurants.
AbbVie: 4 Hidden Keys Investors Must Know To Judge ImmunoGen Acquisition: AbbVie has agreed to acquire ImmunoGen for $10 billion, nearly double its previous ...
seekingalpha.com/article/4655595-abbvie-4-hidden-keys-investors-must-know-to-judge-immunogen-acquisition
Paid articlePaid Buy The Dip In AbbVie? Nope, Not This Time: The valuation of AbbVie is high compared to its growth prospects, making it unattractive. Read more to see our ...
seekingalpha.com/article/4654945-buy-the-dip-in-abbvie-nope-not-this-time
Paid articlePaid AbbVie Makes Another Big Pharma Acquisition. How It’s Putting Its Cash to Work.: AbbVie said late Wednesday it will buy Cerevel Therapeutics for $45 a share ...
barrons.com/articles/abbvie-stock-pharma-acquisition-cerevel-cash-0b2fdcea
Paid articlePaid 100% profit with these stocks?: The wave of takeovers in the pharmaceutical and biotech sector is gaining momentum, especially in the USA ...
boerse-online.de/nachrichten/geld-und-vorsorge/100-gewinn-mit-diesen-aktien-20347483.html
Is Primary Biliary Cholangitis on Your Radar? : Did you know that primary biliary cholangitis (PBC) is the most common of the autoimmune liver diseases? Hear ...
medscape.org/viewarticle/998621
Astra, GSK, AbbVie Accused by Senator Warren of 'Abusing' Drug Patent System
bloomberg.com/news/articles/2023-12-14/astra-abbvie-slammed-by-warren-for-abusing-drug-patent-system
Cerevel options trading surge before AbbVie deal news raises eyebrows
reuters.com/markets/deals/cerevel-options-trading-surge-before-abbvie-deal-news-raises-eyebrows-2023-12-07/
Commentary: Targeted cancer drugs finally live up to the hype: Antibody-drug conjugates could eventually play a much larger role in cancer treatment - and even ...
channelnewsasia.com/commentary/cancer-treatment-antibody-drug-conjugate-immunogen-abbvie-chemo-3969221
Test your knowledge: Which of the following classes is used in treatment of ROS1-positive non-small cell lung cancer?
Take our activity to learn more ➡️ ms.spr.ly/6185iZgqU
Pharma Stocks With Nice Dividends: The RX Investors Need: Healthcare stocks like AbbVie and Johnson & Johnson are cash rich and offer solid dividend growth.
barrons.com/articles/pharma-johnson-abbvie-abbott-dividend-stock-d6a1110c
Paid articlePaid
Lightning update: Dow & Co in plus, Intel, Nike, Sirius XM, Macy's, Cigna and Abbvie strong, Apple, Alphabet, Nvidia and Meta under pressure
deraktionaer.de/artikel/indizes/blitz-update-dow-co-im-plus-intel-nike-sirius-xm-macys-cigna-und-abbvie-stark-apple-alphabet-nvidia-und-meta-unter-druck-20345487.html
US FTC disputes over 100 medical patents listed with FDA including asthma inhalers
reuters.com/business/healthcare-pharmaceuticals/us-ftc-disputes-listing-more-than-100-patents-fda-orange-book-2023-11-07/
Time is of the essence in developing medicines – we need to get faster: Pharmaceutical company AbbVie has a laser focus on identifying opportunities to speed up ...
irishtimes.com/special-reports/2023/11/23/time-is-of-the-essence-in-developing-medicines-we-need-to-get-faster/
Immunogen's AbbVie Deal: Key Insights For Investors And Traders: AbbVie Inc. is acquiring ImmunoGen, Inc. at a 94.6% premium, with shares now trading at a 6 ...
seekingalpha.com/article/4655466-immunogen-abbvie-deal-key-insights-for-investors-and-traders
Paid articlePaid AbbVie swallows SHAREHOLDER hot stock immunogen - Shares shoot up over 80 percent
deraktionaer.de/artikel/pharma-biotech/abbvie-schluckt-aktionaer-hot-stock-immunogen-aktie-schiesst-ueber-80-prozent-hoch-20344649.html
Revance Therapeutics: Not Even Daxxify Can Treat Investor Frown Lines: Revance Therapeutics' share price has been characterised by volatility ever since its IPO ...
seekingalpha.com/article/4654913-revance-therapeutics-not-even-daxxify-can-treat-investors-frown-lines
Paid articlePaid
Fourth constitutional complaint filed against the Financial Stabilization Act: Berlin - After Roche, Abbvie and Janssen, Ipsen is the fourth pharmaceutical ...
aerzteblatt.de/nachrichten/147426/Vierte-Verfassungsbeschwerde-gegen-Finanzstabilisierungsgesetz-eingereicht
AbbVie Lifts Profit Outlook as New Biologics Help Buffer Dwindling Humira Sales: AbbVie Inc. raised its profit outlook for this year and next as demand for newer ...
bloomberg.com/news/articles/2023-10-27/abbvie-lifts-profit-outlook-as-new-biologics-help-buffer-dwindling-humira-sales
AbbVie takes $2.1 bln charge on cancer drug ahead of US price negotiation: AbbVie (ABBV.N), girding for government price negotiations on its big-selling cancer ...
reuters.com/business/healthcare-pharmaceuticals/abbvie-raises-profit-forecast-after-humira-newer-drugs-drive-results-beat-2023-10-27/
AbbVie's blood cancer combo therapy fails in late-stage study: AbbVie (ABBV.N) said on Friday a late-stage study of its experimental combination therapy to treat ...
reuters.com/business/healthcare-pharmaceuticals/abbvies-blood-cancer-combo-therapy-fails-late-stage-study-2023-09-29/
Quick Glance: AbbVie's Blood Cancer Combo Therapy Fails in Late-Stage Study
- AbbVie's experimental combination therapy for a form of blood cancer did not significantly increase the survival rate of patients without disease worsening.
- The combination of AbbVie's Venclyxto and the steroid dexamethasone was tested in patients with relapsed multiple myeloma who had received two or more prior treatments.
- The company reported that 62% of patients treated with the combination therapy showed complete tumor disappearance or reduction in tumor size, compared to 35% of patients treated with the Pomalyst-dexamethasone combination.
- Venclyxto, approved in the U.S. to treat two other types of blood cancer, generated $2.01 billion in revenue in 2022.
Boehringer launches 81% discounted biosimilar of AbbVie's Humira: Germany's Boehringer Ingelheim on Monday launched an unbranded version of its biosimilar of ...
reuters.com/business/healthcare-pharmaceuticals/boehringer-launches-unbranded-humira-biosimilar-81-discount-2023-10-02/
Court denies bid to halt Medicare drug price talks: The decision preserves the Biden administration’s power to begin haggling with drug companies over the prices ...
politico.com/news/2023/09/29/medicare-drug-price-talks-injunction-denied-00117907
New to NewsWall?
Sign up now to get your own personalized news!
Trending topics